UNSPSC 51332504: Benperidol

This classification denotes a dopamine antagonist with the molecular formula C22H24FN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 97O6X78C53, chemically known as 2h-benzimidazol-2-one, 1-(1-(4-(4-fluorophenyl)-4-oxobutyl)-4-piperidinyl)-1,3-dihydro- but generally known as benperidol, which bears US NIH Compound Identifier 16363. Benperidol most often comes in base and hydrochloride forms. European Medicines Agency schedules Benperidol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05727MIG.

UNSPSC 51332504 Benperidol is a Commodity code that in practice captures state and local procurement of pharmaceutical products and medical supplies, though the recent solicitations tagged to this code show minimal direct relevance to benperidol specifically. State and local health departments, county public-health agencies, and cooperative purchasing alliances are the primary issuing bodies, alongside multistate collaborative procurement vehicles. The work solicited ranges from opioid-antagonist medications and drug deactivation systems for community health programs to broad-based generic pharmaceutical and over-the-counter product distribution frameworks, reflecting the code's application to health-related pharmaceutical sourcing rather than a single drug class.

Recent activity appears concentrated in Florida and Minnesota through a multistate cooperative vehicle. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023, under a two-year term with optional one-year renewal. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, with responses due March 26, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, representing exploratory procurement activity rather than a formal competitive bid. The code shows limited but active state and local pharmaceutical procurement, concentrated in health-agency and cooperative-purchasing channels.